The Humanized FcRn Platform: An Essential Tool for Preclinical PK Assessment of Therapeutic Antibody Candidates

September 29, 2021

Greg Christianson, Study Director, In Vivo Services, The Jackson Laboratory speaks about the use of human FcRn transgenic mouse models to select antibody therapeutic candidates with optimum pharmacokinetics predicting their clearance in humans.

The Humanized FcRn Platform: An Essential Tool for Preclinical PK Assessment of Therapeutic Antibody Candidates

A New Way to Study Cytokine Release Syndrome

Poster: A Humanized In Vivo System to Predict Antibody-induced Cytokine Release Syndrome

A Humanized Preclinical in Vivo System to Predict the Immunotoxicity of Antibody Drug Candidates

CRS: FAQs

Choosing the Appropriate Humanized FcRn Mouse Model to Test the Pharmacokinetics of Antibody Therapeutics

JAX Guide: Assessing Antibody Pharmacokinetics Using the JAX FcRn Platform

Poster: Choosing the Appropriate Immune System- Humanized Mouse Model for Immuno-Modulatory Therapies

Human Immune System Engrafted Mice and Their Role in Human Antibody-Based Drug Development

Mode of Action of TCell Bispecific Antibodies and their Combinations with Checkpoint Inhibitors

Testing the Efficacy of Immuno-Modulatory Antibodies in Humanized Mice

The ABC’s of CAR T Cell Therapies